Biopharma

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains. The year witnessed some watershed regulatory...

Novavax, Inc. (NASDAQ: NVAX) shares are trading lower Friday as most COVID-19-related biopharma stocks dropped. The weakness was partly due to the broader market sell-off, triggered by higher bond yields and expectations of removal of monetary policy accommodation. Novavax was down 16.94% at $172....

Opthea Limited, a biotechnology company focussed on retinal diseases, announced Sunday it is seeking an initial public offering in the United States. What Happened: The Melbourne Australia-based biopharmaceutical company will offer American Depositary Shares each of which will represent eight of...

Biopharmaceutical company Epizyme Inc. (NASDAQ: EPZM) on Thursday said that its tazemetostat drug for the treatment of patients with epithelioid sarcoma had been approved by the Food and Drug Administration. What Happened The TAZVERIK drug has been approved, particularly for the...

Clinical-stage biopharma Surface Oncology, Inc. (NASDAQ: SURF) has developed a prosperous pipeline that targets the tumor micro-environment and leverages the innate and adaptive immune system, according to Baird Equity Research.  The Analyst Analyst Michael Ulz initiated coverage of...

M&A activity has begun in the New Year, with the pharma sector leading from the front. Earlier this week, the Wall Street Journal reported Celgene Corporation (NASDAQ: CELG) is pursuing Juno Therapeutics Inc (NASDAQ: JUNO). The report triggered a massive 52-percent upward move in shares of...

Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three months following a negative announcement on an Alzheimer's trial.  The Analyst...

Clinical-stage biopharma company Epizyme Inc (NASDAQ: EPZM)'s tazemetostat has shown effectiveness in treating blood cancers and solid tumors with minimal toxicities in early- and mid-stage trials, according to Morgan Stanley.  Tazemetostat is an EZH2 inhibitor that moderates gene...

The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was all about competition in the CART-T space. Immunotherapy — the fifth pillar of...

The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited incremental reaction, with the direction and magnitude of the moves dependent on the market...

Joshua Schimmer of Piper Jaffray commented in a note that he is "eager to hit the reset button" within the biopharma sector. Schimmer presented a list of potential outcomes and events in 2016 which represent contrarian views or ones that investors "aren't even...